Articles tagged with Astrocytomas
Researchers at the University of Southern California Health Sciences have discovered a new treatment approach that combines laser heat therapy with immunotherapy to improve survival rates for patients with high-grade astrocytoma. Nearly half of patients treated with this combination were still alive after 18 months, exceeding the typic...
A national clinical trial found that abemaciclib, an oral cancer drug, may slow tumor growth in patients with aggressive meningiomas with specific genetic mutations. The trial showed promising results, with a median progression-free survival of 10 months and a median overall survival of 29 months.
Researchers studied clinical features and treatment strategies for managing postoperative space-occupying cysts in brain tumor surgical sites. External drainage using an Ommaya reservoir or direct percutaneous puncture drainage showed favorable results, reducing cyst size and improving patient outcomes.
Researchers at Nagoya University found that localized IDH wild-type histologically diffuse astrocytomas have a poor prognosis similar to the most malignant types of brain and spinal cord tumors. This highlights the importance of proper clinical diagnosis and treatment for patients with gliomas.
A study by Valeria Valente identified genetic alterations promoting aggressiveness in astrocytomas, with correlations to patient survival prognosis. The research aimed to customize treatment to patient needs, potentially predicting tumor behavior through gene signatures.
Researchers found that malignant astrocytoma patients with the IDH1 mutation benefit greatly from surgical removal of as much tumor tissue as possible. This approach significantly improves survival, with average patient survival rates of 13.5 years for those with mutant tumors compared to less than 1.5 years for non-mutant tumors.
Researchers have discovered that pilocytic astrocytomas, a common childhood brain tumor, arise from defective activation of the MAPK signaling pathway. The study provides new insights into the disease and potential targets for treatment, including targeted agents to block overactive MAPK signaling.
Researchers at Johns Hopkins Medicine have discovered a link between the slow growth of childhood brain tumors and a genetic process similar to that seen in skin moles. The study suggests that tumor-suppressor genes are activated, limiting tumor growth.
A single gene defect in the BRAF gene has been linked to pilocytic astrocytoma, a common brain tumor in children. Treatment with kinase inhibitors has shown promise in slowing down growth, paving the way for further research into targeted therapies.
A new mouse model has been developed to study pilocytic astrocytoma (PA), a common pediatric brain tumor. The model uses expression of a mutant BRAF kinase domain in mice and shows that this is sufficient to induce the formation of PA, closely resembling human disease.
A family history of brain tumors is linked to a higher risk of developing the same type of tumor. Researchers found that people with immediate relatives who suffered from glioblastomas or astrocytomas were nearly four and twice as likely to contract the same kind of brain cancer, respectively.
Researchers discovered that duplicated regions of DNA containing the BRAF gene lead to increased tumor growth. Targeting the MAPK pathway, which is downstream of BRAF, may provide a new approach for treating individuals with low-grade astrocytomas.
Researchers at Emory University's Winship Cancer Institute have identified a novel biomarker called 'soluble attractin' that is elevated in patients with malignant astrocytomas. This protein plays a key role in the migration and recurrence of brain tumors, making it a promising target for future therapeutic intervention.
A study found that large amounts of Ki-67 antigen in cancer cells predict the growth and return of pilocytic astrocytoma, a common childhood brain tumor. The presence of this protein increases the risk of cancer recurrence or growth.